Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 2/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.38 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.38 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28430958 | 1.00 | PDGFRB (0.48) | PDGFRBPDGFRAADORA2ARAB9AKMT2A | |
| SCHEMBL29702254 | 1.00 | PDGFRB (0.48) | PDGFRBPDGFRAADORA2ARAB9AKMT2A | |
| SCHEMBL21271507 | 1.00 | PDGFRB (0.48) | PDGFRBPDGFRAADORA2ARAB9AKMT2A | |
| SCHEMBL20154295 | 1.00 | PDGFRB (0.48) | PDGFRBPDGFRAADORA2ARAB9AKMT2A | |
| SCHEMBL30238682 | 0.82 | ALDH1A1 (0.51) | RAB9AKMT2ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL28898482 | 0.82 | ALDH1A1 (0.51) | RAB9AKMT2ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL28898481 | 0.82 | ALDH1A1 (0.51) | RAB9AKMT2ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL28460239 | 0.78 | ALDH1A1 (0.50) | KMT2ASMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL28460241 | 0.78 | ALDH1A1 (0.50) | KMT2ASMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL30239589 | 0.78 | ALDH1A1 (0.50) | KMT2ASMN1; SMN2KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-02 | — | — | US | disclosed |
| US-11292802-B2 | Substituted tetrahydropyrrolo[1,2-a]pyrazines as alpha v integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-04-05 | — | — | US | disclosed |
| EP-3707142-B1 | PYRROLOPYRAZINE DERIVATIVES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-12-08 | — | — | EP | disclosed |
| US-20210246136-A1 | CYCLOBUTANES- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-08-12 | — | — | US | disclosed |
| US-20210163501-A1 | PYRROLOPYRAZINE DERIVATIVES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MAYERS SQUIBB COMPANY (US) | 2021-06-03 | — | — | US | disclosed |
| US-11014922-B2 | Cyclobutane- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-25 | — | — | US | disclosed |
| EP-3538528-B1 | PYRROLE AMIDES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-12-23 | — | — | EP | disclosed |
| US-10717736-B2 | Pyrrole amides as alpha V integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-07-21 | — | — | US | disclosed |
| US-20190270741-A1 | CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-05 | — | — | US | disclosed |
| US-20190256512-A1 | PYRROLE AMIDES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190256512-A1 | PYRROLE AMIDES AS ALPHA V INTEGRIN INHIBITORS | ITGAV, ITGB1, ITGA1 | PDGFRB 59/4885PDGFRA 91/4885ADORA2A 3442/4885 |
| US-20190270741-A1 | CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | ITGB1, ITGAV, ITGA1 | PDGFRB 47/4885PDGFRA 95/4885ADORA2A 828/4885 |
| US-20210163501-A1 | PYRROLOPYRAZINE DERIVATIVES AS ALPHA V INTEGRIN INHIBITORS | ITGB1, ITGAV, ITGB5 | PDGFRB 42/4885PDGFRA 67/4885ADORA2A 3162/4885 |
| US-11292802-B2 | Substituted tetrahydropyrrolo[1,2-a]pyrazines as alpha v integrin inhibitors | ITGB1, ITGAV, ITGA1 | PDGFRB 53/4885PDGFRA 86/4885ADORA2A 1685/4885 |
| US-20210246136-A1 | CYCLOBUTANES- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | ITGB1, ITGAV, ITGA1 | PDGFRB 46/4885PDGFRA 90/4885ADORA2A 836/4885 |
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | ITGB1, ITGB2, ITGA1 | PDGFRB 39/4885PDGFRA 89/4885ADORA2A 985/4885 |
| US-11014922-B2 | Cyclobutane- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | ITGB1, ITGB2, ITGA1 | PDGFRB 40/4885PDGFRA 97/4885ADORA2A 774/4885 |
| US-10717736-B2 | Pyrrole amides as alpha V integrin inhibitors | ITGAV, ITGB1, ITGA1 | PDGFRB 59/4885PDGFRA 91/4885ADORA2A 3442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.